AU2001264515A1 - Melphalan derivatives and their use as cancer chemotherapeutic drugs - Google Patents
Melphalan derivatives and their use as cancer chemotherapeutic drugsInfo
- Publication number
- AU2001264515A1 AU2001264515A1 AU2001264515A AU6451501A AU2001264515A1 AU 2001264515 A1 AU2001264515 A1 AU 2001264515A1 AU 2001264515 A AU2001264515 A AU 2001264515A AU 6451501 A AU6451501 A AU 6451501A AU 2001264515 A1 AU2001264515 A1 AU 2001264515A1
- Authority
- AU
- Australia
- Prior art keywords
- chemotherapeutic drugs
- cancer chemotherapeutic
- melphalan
- melphalan derivatives
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical class OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940044683 chemotherapy drug Drugs 0.000 title 1
- 230000002152 alkylating effect Effects 0.000 abstract 2
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 231100000315 carcinogenic Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21122700P | 2000-06-13 | 2000-06-13 | |
| SE0002202 | 2000-06-13 | ||
| US60211227 | 2000-06-13 | ||
| SE0002202A SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | New peptides |
| PCT/SE2001/001318 WO2001096367A1 (en) | 2000-06-13 | 2001-06-11 | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001264515A1 true AU2001264515A1 (en) | 2001-12-24 |
Family
ID=20280067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001264515A Abandoned AU2001264515A1 (en) | 2000-06-13 | 2001-06-11 | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1290011B1 (https=) |
| JP (1) | JP4798930B2 (https=) |
| AT (1) | ATE458746T1 (https=) |
| AU (1) | AU2001264515A1 (https=) |
| CA (1) | CA2408501C (https=) |
| DK (1) | DK1290011T3 (https=) |
| ES (1) | ES2341702T3 (https=) |
| PT (1) | PT1290011E (https=) |
| SE (1) | SE0002202D0 (https=) |
| WO (1) | WO2001096367A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374907A3 (en) * | 2002-06-24 | 2004-01-07 | Ghanem Elias c/o Institut Jules Bordet Ghanem | Drug transport and delivery system |
| DE10239832A1 (de) * | 2002-08-29 | 2004-03-18 | Lipal Biochemicals AG c/o University of Zurich | Sarcolysyl-Derivate und Verfahren zu deren Herstellung |
| WO2011011865A1 (en) * | 2009-07-29 | 2011-02-03 | 3R Valo, S.E.C. | Anticancer agents based on amino acid derivatives |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| DK2701720T3 (en) * | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| KR102122429B1 (ko) * | 2011-04-28 | 2020-06-12 | 온코펩타이드즈 아베 | 세포독성 디펩티드의 동결건조 제제 |
| KR102226082B1 (ko) * | 2012-10-26 | 2021-03-10 | 온코펩타이드즈 아베 | 멜팔란 플루펜아미드의 동결건조 제제 |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| CN108864251B (zh) * | 2018-06-30 | 2022-06-14 | 大连理工大学 | 一类氨肽酶n激活的药物前体化合物及其制备方法和应用 |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| WO2020201542A1 (en) | 2019-04-03 | 2020-10-08 | Oncopeptides Ab | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| WO2022167087A1 (en) * | 2021-02-05 | 2022-08-11 | Oncopeptides Ab | Peptidase enhanced cytotoxic dipeptides |
| EP4083052A1 (en) | 2021-04-29 | 2022-11-02 | BKmdcl AB | Peptide conjugates of melphalan for the treatment of cancer |
| ES3034388T3 (en) | 2021-06-01 | 2025-08-18 | Synthon Bv | Process for making melflufen or a salt thereof |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| JP2024524552A (ja) | 2021-07-08 | 2024-07-05 | オンコペプティデス エービー | 多発性骨髄腫の治療に使用するためのメルフルフェン |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
| WO2026057823A1 (en) | 2024-09-13 | 2026-03-19 | Oncopeptides Ab | Bis-chloroethylamino derivatives for treating leukemia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
-
2000
- 2000-06-13 SE SE0002202A patent/SE0002202D0/xx unknown
-
2001
- 2001-06-11 CA CA2408501A patent/CA2408501C/en not_active Expired - Lifetime
- 2001-06-11 ES ES01938945T patent/ES2341702T3/es not_active Expired - Lifetime
- 2001-06-11 EP EP01938945A patent/EP1290011B1/en not_active Expired - Lifetime
- 2001-06-11 AU AU2001264515A patent/AU2001264515A1/en not_active Abandoned
- 2001-06-11 AT AT01938945T patent/ATE458746T1/de not_active IP Right Cessation
- 2001-06-11 WO PCT/SE2001/001318 patent/WO2001096367A1/en not_active Ceased
- 2001-06-11 DK DK01938945.1T patent/DK1290011T3/da active
- 2001-06-11 PT PT01938945T patent/PT1290011E/pt unknown
- 2001-06-11 JP JP2002510508A patent/JP4798930B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2408501A1 (en) | 2001-12-20 |
| EP1290011A1 (en) | 2003-03-12 |
| CA2408501C (en) | 2011-01-18 |
| DK1290011T3 (da) | 2010-06-07 |
| EP1290011B1 (en) | 2010-02-24 |
| PT1290011E (pt) | 2010-05-11 |
| ES2341702T3 (es) | 2010-06-25 |
| WO2001096367A1 (en) | 2001-12-20 |
| JP2004503564A (ja) | 2004-02-05 |
| SE0002202D0 (sv) | 2000-06-13 |
| JP4798930B2 (ja) | 2011-10-19 |
| ATE458746T1 (de) | 2010-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001264515A1 (en) | Melphalan derivatives and their use as cancer chemotherapeutic drugs | |
| IL140338A0 (en) | Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| NZ592510A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| AU2002229510A1 (en) | Combined use of factor vii polypeptides and factor viii polypeptides | |
| WO2001010457A3 (en) | Pharmaceutical compositions containing tripeptides | |
| HK1039108A1 (zh) | 以n-氰甲基酰胺作为蛋白酶抑制剂 | |
| MX9505182A (es) | Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p. | |
| NZ534919A (en) | Bioactive keratin peptides | |
| WO2000012541A3 (en) | Cytotoxic peptides modified by bulky or lipophilic moieties | |
| BR9713404A (pt) | ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos. | |
| AU3960400A (en) | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv | |
| WO2004091497A3 (en) | Methods and compositions for increasing the anaerobic working capacity in tissues | |
| BR0014378A (pt) | Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| WO2002096348A3 (fr) | Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux | |
| AU2001269927A1 (en) | Thrombomodulin analogs for pharmaceutical use | |
| WO2004016741A3 (en) | Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use | |
| WO2001068676A3 (de) | Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel | |
| AU2921999A (en) | Indole-2,3-dione-3-oxime derivatives for therapeutic use | |
| WO2003004517A3 (en) | Peyers's patch and/or m-celle targeting ligands | |
| WO2002046225A3 (en) | Use of sarp-1 for the treatment and/or prevention of scleroderma | |
| WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
| AU3739500A (en) | Protease resistant flint analogs | |
| CA2420640A1 (en) | Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients |